Moderate immunohistochemical expression of her-2 (2) without her-2 gene amplification is a negative prognostic factor in early breast cancer

Oncologist

Volumn 17, Issue 11, 2012, Pages 1418-1425

  Rossi, Valentina ^a   Sarotto, Ivana ^a   Maggiorotto, Furio ^a   Berchialla, Paola ^b   Kubatzki, Franziska ^a   Tomasi, Nicoletta ^a   Redana, Stefania ^a   Martinello, Rossella ^a   Valabrega, Giorgio ^a   Aglietta, Massimo ^a   Ponzone, Riccardo ^c   Montemurro, Filippo ^a,d  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d Fondazione del Piemonte per l'Oncologia   (Italy)

Author keywords

Breast cancer; Fluorescence in situ hybridization; Her 2; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84869381645     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0194     Document Type: Article

References (30)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
3. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
4. Rilke F, Colnaghi MI, Cascinelli N et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-49.
5. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. The Oncologist 1998;3:237-252.
6. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
7. Berry DA, Muss HB, Thor AD et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471-3479.
8. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008;100:14-20.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
10. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
11. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
12. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29: 3366-3373.
13. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236-244.
14. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
15. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5:63-69.
16. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical falsepositives do not get the message. J Clin Oncol 2001;19: 2714-2721.
17. Ross JS, Fletcher JA, Linette GP et al. The Her-2/ neu gene and protein in breast cancer 2003: Biomarker and target of therapy. The Oncologist 2003;8:307-325.
18. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.
19. Perez EA, Reinholz MM, Hillman DW et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28: 4307-4315.
20. National Surgical Breast and Bowel Project trial 2012;47. Available at http://www.nsabp.pitt.edu/B-47.asp, accessed June 10, 2012.
21. Hilsenbeck SG, Ravdin PM, de Moor CA et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52:227-237.
22. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-750.
23. Perou CM, Sr-lie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
24. Srrlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
25. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
26. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-1675.
27. Ménard S, Balsari A, Tagliabue E et al. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 2008;19:1706-1712.
28. Gilcrease MZ, Woodward WA, Nicolas MM et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 2009;33:759-767.
29. Minner S, Jessen B, Stiedenroth L et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-1560.
30. Engelsen IB, Stefansson IM, Beroukhim R et al. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008;32:307-316.